Literature DB >> 21030449

Increased epithelial permeability in pulmonary fibrosis in relation to disease progression.

N S L Goh1, S R Desai, C Anagnostopoulos, D M Hansell, R K Hoyles, H Sato, C P Denton, C M Black, R M du Bois, A U Wells.   

Abstract

Epithelial injury contributes to pathogenesis in idiopathic pulmonary fibrosis (IPF) but its role in the interstitial lung disease (ILD) of systemic sclerosis (SSc) is uncertain. We quantified the prognostic significance of inhaled technetium-99m ((99m)Tc)-labelled diethylene triamine pentacetate (DTPA) pulmonary clearance, a marker of the extent of epithelial injury, in both diseases. Baseline (99m)Tc-DTPA pulmonary clearance was evaluated retrospectively in patients with SSc-ILD (n = 168) and IPF (n = 97) against mortality and disease progression. In SSc-ILD, the rapidity of total clearance (hazard ratio (HR) 1.02, 95% CI 1.01-1.03; p = 0.001) and the presence of abnormally rapid clearance (HR 2.10; 95% CI 1.25-3.53; p = 0.005) predicted a shorter time to forced vital capcity (FVC) decline, independent of disease severity. These associations were robust in both mild and severe disease. By contrast, in IPF, delayed clearance of the slow component, an expected consequence of honeycomb change, was an independent predictor of a shorter time to FVC decline (HR 1.01, 95% CI 1.00-1.02; p<0.01). Epithelial injury should be incorporated in pathogenetic models in SSc-ILD. By contrast, outcome is not linked to the overall extent of epithelial injury in IPF, apart from abnormalities ascribable to honeycombing, suggesting that core pathogenetic events may be more spatially focal in that disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21030449     DOI: 10.1183/09031936.00010910

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

Review 1.  Novel Imaging Approaches in Systemic Sclerosis-Associated Interstitial Lung Disease.

Authors:  Sydney B Montesi; Peter Caravan
Journal:  Curr Rheumatol Rep       Date:  2019-04-25       Impact factor: 4.592

Review 2.  Interstitial lung disease in connective tissue disease--mechanisms and management.

Authors:  Athol U Wells; Christopher P Denton
Journal:  Nat Rev Rheumatol       Date:  2014-09-30       Impact factor: 20.543

3.  Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis.

Authors:  Akihiko Sokai; Kiminobu Tanizawa; Tomohiro Handa; Kumiko Kanatani; Takeshi Kubo; Kohei Ikezoe; Yoshinari Nakatsuka; Shinsaku Tokuda; Toru Oga; Toyohiro Hirai; Sonoko Nagai; Kazuo Chin; Michiaki Mishima
Journal:  ERJ Open Res       Date:  2017-08-30

Review 4.  "A Chain Only as Strong as Its Weakest Link": An Up-to-Date Literature Review on the Bidirectional Interaction of Pulmonary Fibrosis and COVID-19.

Authors:  Radu Crisan-Dabija; Cristina Alice Pavel; Iolanda Valentina Popa; Andrei Tarus; Alexandru Burlacu
Journal:  J Proteome Res       Date:  2020-09-17       Impact factor: 4.466

5.  Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis.

Authors:  Kimberly Showalter; Aileen Hoffmann; Carrie Richardson; David Aaby; Jungwha Lee; Jane Dematte; Rishi Agrawal; Hatice Savas; Xiaoping Wu; Rowland W Chang; Monique Hinchcliff
Journal:  J Rheumatol       Date:  2021-07-15       Impact factor: 4.666

6.  Circulating biomarkers of interstitial lung disease in systemic sclerosis.

Authors:  Harpreet K Lota; Elisabetta A Renzoni
Journal:  Int J Rheumatol       Date:  2012-09-03

7.  Electret filter collects more exhaled albumin than glass condenser: A method comparison based on human study.

Authors:  Ziru Jia; Hongying Liu; Wang Li; Dandan Xie; Ke Cheng; Xitian Pi
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.